

Mary F Paine

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3990686/mary-f-paine-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

5,075
citations

36
h-index

70
g-index

105
ext. papers

5,557
ext. citations

4.7
avg, IF

5.38
L-index

#	Paper	IF	Citations
92	The human intestinal cytochrome P450 "pie". <i>Drug Metabolism and Disposition</i> , 2006 , 34, 880-6	4	666
91	Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 491-502	6.1	504
90	First-pass metabolism of midazolam by the human intestine. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 14-24	6.1	394
89	The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. <i>Drug Metabolism Reviews</i> , 2001 , 33, 273-97	7	327
88	Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. <i>Molecular Pharmacology</i> , 1997 , 51, 741-54	4.3	287
87	P-glycoprotein increases from proximal to distal regions of human small intestine. <i>Pharmaceutical Research</i> , 2003 , 20, 1595-9	4.5	220
86	Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 14-23	6.1	135
85	A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. <i>American Journal of Clinical Nutrition</i> , 2006 , 83, 1097-105	7	122
84	Herb-drug interactions: challenges and opportunities for improved predictions. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 301-17	4	113
83	Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 426-33	4	94
82	Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 490-509	4	91
81	Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. <i>Pharmacology & Therapeutics</i> , 2012 , 136, 186-201	13.9	82
80	Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 1146-53	4	78
79	Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 605-18	6.1	77
78	Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 312, 1151-60	4.7	76
77	CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 1985-94	4	75
76	Two flavonolignans from milk thistle (<i>Silybum marianum</i>) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 332, 1081-7	4.7	67

75	Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. <i>Pharmaceutical Research</i> , 1999 , 16, 1199-205	4.5	65
74	Diamidines for human African trypanosomiasis. <i>Current Opinion in Investigational Drugs</i> , 2010 , 11, 876-83		59
73	United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. <i>Toxicology Reports</i> , 2020 , 7, 386-402	4.8	55
72	6 β -OH dihydroxybergamottin contributes to the grapefruit juice effect. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 569-79	6.1	51
71	Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 941-8	4.7	50
70	Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach. <i>Natural Product Reports</i> , 2019 , 36, 1196-1221	15.1	49
69	Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 67-80	5.5	49
68	A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. <i>Toxicological Sciences</i> , 2012 , 130, 416-26	4.4	47
67	Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 863-71	7	46
66	Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 2067-75	4	46
65	Understanding the transport properties of metabolites: case studies and considerations for drug development. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 650-64	4	42
64	Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 174-86	4.7	42
63	Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1675-83	4	39
62	The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 146-54	4	39
61	Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (<i>Camellia sinensis</i>) as a Case Study. <i>Journal of Natural Products</i> , 2017 , 80, 1457-1466	4.9	38
60	Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 462-70	4.7	37
59	Isolation and identification of intestinal CYP3A inhibitors from cranberry (<i>Vaccinium macrocarpon</i>) using human intestinal microsomes. <i>Planta Medica</i> , 2011 , 77, 265-70	3.1	37
58	A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. <i>Proteomics</i> , 2008 , 8, 4186-96	4.8	37

57	Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 524-35	6.1	37
56	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. <i>Pharmacology & Therapeutics</i> , 2019 , 201, 25-38	13.9	36
55	Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 514-22	4	35
54	A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1662-70	4	30
53	Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2012 , 6, e1734	4.8	30
52	Influence of dietary substances on intestinal drug metabolism and transport. <i>Current Drug Metabolism</i> , 2010 , 11, 778-92	3.5	30
51	Immunochemical identification of UGT isoforms in human small bowel and in caco-2 cell monolayers. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 273, 1053-7	3.4	30
50	The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 1465-9	4	25
49	Enhanced bioactivity of silybin B methylation products. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 742-7	3.4	23
48	Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 334, 410-8	4.7	23
47	Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 34-41	4	22
46	Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 337, 503-12	4.7	22
45	New insights into drug absorption: studies with sirolimus. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 463-7	3.2	21
44	Effects of Common CYP1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis. <i>Clinical and Translational Science</i> , 2019 , 12, 39-46	4.9	20
43	Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 1008-1017	4	19
42	Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 3919-26	3.4	19
41	Rapid Quantitation of Furanocoumarins and Flavonoids in Grapefruit Juice using Ultra-Performance Liquid Chromatography. <i>Phytochemical Analysis</i> , 2013 , 24, 654-60	3.4	19
40	A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 6-17	4	19

39	A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 2312-5	4	19
38	Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1353-9	4	17
37	"Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents. <i>Regulatory Toxicology and Pharmacology</i> , 2020 , 113, 104642	3.4	17
36	Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 552-560	4	17
35	Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 701-10	4.5	17
34	Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice. <i>Biopharmaceutics and Drug Disposition</i> , 2017 , 38, 251-259	1.7	16
33	Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 2136-42	4	16
32	Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003409	4.8	15
31	Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1041-1045	4	15
30	Can oral midazolam predict oral cyclosporine disposition?. <i>European Journal of Pharmaceutical Sciences</i> , 2000 , 12, 51-62	5.1	15
29	Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 55-64	6.1	15
28	Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1046-1052	4	14
27	Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2013 , 7, e2230	4.8	14
26	ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 781-784	6.1	14
25	Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 643-51	3.8	13
24	Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	12
23	Follow that botanical: Challenges and recommendations for assessing absorption, distribution, metabolism and excretion of botanical dietary supplements. <i>Food and Chemical Toxicology</i> , 2018 , 121, 194-202	4.7	11
22	Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 98, 260-5	3.5	9

21	Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014 , 351, 576-84	4.7	9
20	Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 376, 64-73	4.7	8
19	Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. <i>Toxicol</i> , 2019 , 162, 1-8	2.8	7
18	A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect". <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 982-90	2.9	7
17	Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 518-28	4	6
16	A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 371, 385-393	4.7	5
15	Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 1734-43	4	5
14	Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 1018-1027	4	4
13	Effect of grapefruit juice on the disposition of omeprazole. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 213-217	3.8	4
12	Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1342-1352	6.1	4
11	Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. <i>Phytotherapy Research</i> , 2021 , 35, 3286-3297	6.7	3
10	Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach. <i>Pharmacological Reviews</i> , 2021 , 73, 847-859	22.5	2
9	A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 1104-1112	4	1
8	Adapting regulatory drug-drug interaction guidance to design clinical pharmacokinetic natural product-drug interaction studies: A NaPDI Center recommended approach. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
7	Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: An International Transporter Consortium perspective. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
6	Indinavir Increases Midazolam -Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 724-731	4	0
5	Drug Metabolism, Transport, and Pharmacogenomics 2015 , 626-638		
4	Heterotropic Cooperativity for CYP3A4-Mediated 1?-Hydroxylation of Midazolam by Berberine: An In Silico Modeling and Simulation Study. <i>FASEB Journal</i> , 2019 , 33, 508.5	0.9	

3 Sex-specific pharmacological differences **2022**, 405-424

2 Characterizing the abuse potential of loperamide via physiologically-based pharmacokinetic/pharmacodynamic modeling and simulation (1053.6). *FASEB Journal*, **2014**, 28, 1053.6 ^{0.9}

1 Assessing drug interaction risk of the grapefruit juice component and dietary supplement 6?,7?-dihydroxybergamottin via physiologically-based pharmacokinetic modeling and simulation. *FASEB Journal*, **2013**, 27, 1103.4 0.9